

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA BIOTECH SERVICES HOLDINGS LIMITED

中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

EXPIRY OF LONG STOP DATE AND LAPSE OF (1) MAJOR TRANSACTION IN RELATION TO THE CAPITAL INJECTION IN AND DEEMED DISPOSAL OF EQUITY INTEREST IN PENGBO (HAINAN) MEDICAL TECHNOLOGY CO., LTD#; AND (2) MAJOR TRANSACTION IN RELATION TO THE GRANT OF THE REPURCHASE RIGHTS

Reference is made to the announcement (the “**Announcement**”) of China Biotech Services Holdings Limited (the “**Company**”) dated 5 August 2024 in relation to, among others, the Capital Injection Agreement and the transactions contemplated thereunder (including, but not limited to, the Capital Injection and the Repurchase Rights), the announcements dated 26 August 2024, 23 September 2024, 4 October 2024 and 4 November 2024 (the “**Delay Announcements**”) in relation to the delay in despatch of the Circular, and the announcements dated 3 September 2024, 30 September 2024 and 30 October 2024 (the “**Supplemental Announcements**”, and together with the Announcement and the Delay Announcements, the “**Announcements**”) in relation to the entering into of the Supplemental Agreement, the second supplemental agreement (the “**Second Supplemental Agreement**”) dated 30 September 2024 and the Third Supplemental Agreement (as defined below and together with the Supplemental Agreement and the Second Supplemental Agreement, the “**Supplemental Agreements**”). Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the Announcements.

Pursuant to the third supplemental agreement (the “**Third Supplemental Agreement**”) to the Capital Injection Agreement, entered into among Pengbo (Hainan), Dynamic Healthcare, CBSH Flourish, Mr. Liu, the Company and Hubei Weiyou on 30 October 2024, the Parties had agreed to extend the date for fulfillment of the conditions precedent to 15 November 2024 (the “**Long Stop Date**”).

The Board hereby announces that as of 15 November 2024, the conditions precedent were not fulfilled (or waived) and no agreement was reached by the Parties to further extend the Long Stop Date. Hence, the Capital Injection Agreement (as supplemented by the Supplemental Agreements) has lapsed. The Directors consider that the lapse of the Capital Injection Agreement will have no material adverse impact on the Group's business, operations, and financial position.

As the Capital Injection Agreement (as supplemented by the Supplemental Agreements) had lapsed on 15 November 2024, the Company will no longer despatch the Circular in relation to the Capital Injection Agreement and the transactions contemplated thereunder (including, but not limited to, the Capital Injection and the Repurchase Rights) to the Shareholders for information purposes.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

for identification purposes only

Hong Kong, 15 November 2024

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song and three independent non-executive Directors, namely Mr. Yan Guoxiang, Dr. Guo Yuantao and Mr. Qian Hongji.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the "Latest Listed Company Information" page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.